Roche’s announcement that it would pay $310 million for rights to a hypertension treatment invented by the biotech firm Alnylam is evidence of the industry's renewed interest in cardiovascular treatments.
Comments
\(°ロ\)
There's nothing here…
Roche’s announcement that it would pay $310 million for rights to a hypertension treatment invented by the biotech firm Alnylam is evidence of the industry's renewed interest in cardiovascular treatments.